Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Assets Average (2019 - 2025)

Historic Assets Average for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $1.0 billion.

  • BridgeBio Pharma's Assets Average rose 4242.21% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 4242.21%. This contributed to the annual value of $732.9 million for FY2024, which is 2533.76% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Assets Average of $1.0 billion as of Q3 2025, which was up 4242.21% from $980.9 million recorded in Q2 2025.
  • BridgeBio Pharma's Assets Average's 5-year high stood at $1.1 billion during Q2 2021, with a 5-year trough of $564.7 million in Q2 2023.
  • For the 5-year period, BridgeBio Pharma's Assets Average averaged around $808.8 million, with its median value being $821.9 million (2024).
  • Its Assets Average has fluctuated over the past 5 years, first tumbled by 3259.2% in 2023, then soared by 4554.58% in 2024.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Assets Average stood at $897.2 million in 2021, then fell by 24.66% to $675.9 million in 2022, then decreased by 11.13% to $600.7 million in 2023, then surged by 31.87% to $792.2 million in 2024, then surged by 31.19% to $1.0 billion in 2025.
  • Its Assets Average was $1.0 billion in Q3 2025, compared to $980.9 million in Q2 2025 and $900.5 million in Q1 2025.